AN OPEN-LABEL STUDY TO DETERMINE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM ORAL LACOSAMIDE (LCM) AS ADJUNCTIVE THERAPY IN CHILDREN WITH EPILEPSY
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Lacosamide (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB
- 17 Dec 2021 Status changed from active, no longer recruiting to completed.
- 17 Nov 2021 This trial has been completed in Italy (End Date: 18 May 2021), according to European Clinical Trials Database record.
- 07 Jul 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.